Radiation recall - Another call with tamoxifen

Acta Oncologica

Volumn 38, Issue 7, 1999, Pages 955-960

  Boström, Åsa ^a   Sjölin Forsberg, Gunilla ^a,b   Wilking, Nils ^c   Bergh, Jonas ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Medical Product Agency   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DACTINOMYCIN; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; TAMOXIFEN; TOREMIFENE;

ADJUVANT THERAPY; ADULT; ALOPECIA; ARTICLE; BREAST CANCER; CASE REPORT; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RADIATION INJURY; RASH; SKIN ATROPHY; SKIN DISEASE; TREATMENT OUTCOME; URTICARIA;

EID: 0032710047     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432653     Document Type: Article

References (17)

1. 1. Craig Jordon V. The development of tamoxifen for breast cancer therapy. In: Craig Jordon V, ed. Long-term tamoxifen treatment for breast cancer. Wisconsin, USA: University of Wisconsin Press, 1994: 4-26.
2. 2. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1466.
3. 3. Fritsch M, Wolf DM. Symptomatic side effects of tamoxifen therapy. In: Craig Jordon V, ed. Long-term tamoxifen treatment for breast cancer. Wisconsin, USA: University of Wisconsin Press, 1994: 236-55.
4. 4. Parry BR. Radiation recall induced by tamoxifen. Lancet 1992; 340: 49.
5. 5. Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agent. J Am Acad Dermatol 1983; 9: 654-63.
6. 6. Eifel PJ, McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin's lymphoma of Waldeyer's ring. Int J Radiat Oncol Biol Phys 1989; 17: 907-8.
7. 7. Raghaven V, Bloomer W, Merkel D. Taxol and radiation recall dermatitis. Lancet 1994; 341: 1354.
8. 8. Shenkier T, Gelman K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol 1994; 12: 439.
9. 9. Del Giudice SM, Gerstley JK. Sunlight-induced radiation recall. Int Dermatol 1988; 27: 415-6.
10. 10. Edwards R, Lindquist EN, Wilhelm B-E. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156-8.
11. 11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast Bowel Project P-1 Study. J Natl Acad Dermatol 1998; 90: 1371-88.
12. 12. James WD, Odom RB. Late subcutaneous fibrosis following megavoltage radotherapy. J Am Acad Dermatol 1980; 3: 616-8.
13. 13. Turesson I, Notter G. The influence of the overall treatment time in radiotherapy on the acute reaction: comparison of the effects of daily and twice-a-day-week fraction on human skin. Int J Radiat Oncol Biol Phys 1984; 10: 607-19.
14. 14. Turesson I. Individual variation and dose dependency in the progression rate of skin telangiectasia. Int J Radiat Oncol Biol Phys 1990; 19: 1569-74.
15. 15. Fromson JM, Pearson S, Bramah JM. The metabolism of tamoxifen (1CI 46.474) Part II: in female patients. Xenobiotica 1973; 3: 711-4.
16. 16. Kanagas L. Introduction to toremifene. Breast Cancer Res Treat 1990; 16 Suppl: S3-S7.
17. 17. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer; comparison of safety and efficacy. J Clin Oncol 1998; 16: 348-53.